Vivos Therapeutics
VVOS
19 hedge funds and large institutions have $1.34M invested in Vivos Therapeutics in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
1.83% less ownership
Funds ownership: 9.15% → 7.32% (-1.8%)
17% less funds holding
Funds holding: 23 → 19 (-4)
37% less capital invested
Capital invested by funds: $2.13M → $1.34M (-$793K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$527K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$184K |
| 3 |
AWA
Acorn Wealth Advisors
Grand Blanc,
Michigan
|
+$36.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$31.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$620K |
| 2 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
-$310K |
| 3 |
Renaissance Technologies
New York
|
-$122K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$13.4K |
| 5 |
Morgan Stanley
New York
|
-$2.62K |
VVOS Hedge Fund Activity: Q4 2025 in Review
19 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q4 2025, worth a combined $1.34M — down 37% from $2.13M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VVOS and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $527K. The largest seller was Connective Capital Management, exiting entirely with an estimated $620K sold.
- 19 institutional investors held Vivos Therapeutics (VVOS) as of Q4 2025, down from 23 in Q3 2025.
- Funds reported $1.34M of Vivos Therapeutics stock for Q4 2025, down 37% quarter-over-quarter.
- 1 fund opened new Vivos Therapeutics positions in Q4 2025 and 5 closed out, a net change of -4 holders.
- The largest Vivos Therapeutics buyer in Q4 2025 was Vanguard Group, an estimated $527K added.
- The largest Vivos Therapeutics seller in Q4 2025 was Connective Capital Management, an estimated $620K sold.
Based on aggregated 13F filings for Q4 2025.